8/27/2008 First Gene Associated
with Dry Macular Degeneration Found Findings indicate possible adverse consequences to new RNA therapies In a study that underscores the important role that individual genetic profiles will play in the development of new therapies for disease, a multi-institutional research team — led... More...
Currently, there is no treatment for the majority of patients with dry AMD and other inherited forms
of dry macular degeneration that result from the accumulation of bisretinoids.
In dry macular degeneration, the most common form of this eye disease, yellowish cellular deposits called drusen (extracellular waste products from metabolism) form under the retina.
They have joined forces with CHS Pharma, Inc., a South Florida - based biotechnology development company that has an intellectual property portfolio for potential treatments related to ischemic stroke,
dry macular degeneration as well as other age - related disorders such as Alzheimer's disease, to further develop and commercialize this promising technology.
Dry macular degeneration can cause slightly blurred central vision, and this area grows larger as the disease progresses.
In the atrophic form of
dry macular degeneration, patients will generally experience blind spots in the center of their vision and in advanced stages may ultimately experience total central vision.